Recent Advances in Antibody Therapeutics
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinica...
Enregistré dans:
| Format: | Online |
|---|---|
| Langue: | anglais |
| Publié: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Sujets: | |
| Accès en ligne: | ONIX_20220706_9783036543536_3 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1869531201206747136 |
|---|---|
| collection | Directory of Open Access Books |
| description | Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies |
| format | Online |
| id | doab-20.500.12854ir-87408 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-874082024-03-28T03:32:59Z Recent Advances in Antibody Therapeutics Heo, Yong-Seok interleukin 33 ST2 receptor scFv C2_2E12 bladder cancer antibodies immune checkpoint inhibitors antibody-drug conjugates sacituzumab govitecan enfortumab vedotin erdafitinib cost-effectiveness G protein-coupled receptor membrane protein antigen therapeutic antibody anti-angiogenesis delta-like ligand irinotecan paclitaxel VEGF SARS-CoV-2 spike protein receptor-binding domain phage display monoclonal antibody cytomegalovirus peptide/major histocompatibility complex class I complex T-cell-receptor-like antibody affinity maturation yeast surface display combinatorial antibody library agonist antibody cell fate bispecific antibodies bioassays mechanisms of action binding assays potency assays atherosclerosis inflammation antibody therapy blood–brain barrier antibody pharmacokinetics disposition biochemical and physicochemical properties Fc binding receptor-mediated transcytosis brain shuttle molecular Trojan horse transferrin anti-cancer antibody antibody engineering biophysical properties computational methods research cell bank antibody therapeutics recombinant antibodies intracellular antibodies single-chain antibody fragment nanobody Human papillomaviruses HPV oncoproteins HPV-associated cancer HPV cancer therapy asthma refractory asthma biomarker n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies 2022-07-06T11:48:10Z 2022-07-06T11:48:10Z 2022 book ONIX_20220706_9783036543536_3 9783036543536 9783036543543 https://directory.doabooks.org/handle/20.500.12854/87408 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5595 https://mdpi.com/books/pdfview/book/5595 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-4354-3 10.3390/books978-3-0365-4354-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036543536 9783036543543 238 Basel open access |
| spellingShingle | interleukin 33 ST2 receptor scFv C2_2E12 bladder cancer antibodies immune checkpoint inhibitors antibody-drug conjugates sacituzumab govitecan enfortumab vedotin erdafitinib cost-effectiveness G protein-coupled receptor membrane protein antigen therapeutic antibody anti-angiogenesis delta-like ligand irinotecan paclitaxel VEGF SARS-CoV-2 spike protein receptor-binding domain phage display monoclonal antibody cytomegalovirus peptide/major histocompatibility complex class I complex T-cell-receptor-like antibody affinity maturation yeast surface display combinatorial antibody library agonist antibody cell fate bispecific antibodies bioassays mechanisms of action binding assays potency assays atherosclerosis inflammation antibody therapy blood–brain barrier antibody pharmacokinetics disposition biochemical and physicochemical properties Fc binding receptor-mediated transcytosis brain shuttle molecular Trojan horse transferrin anti-cancer antibody antibody engineering biophysical properties computational methods research cell bank antibody therapeutics recombinant antibodies intracellular antibodies single-chain antibody fragment nanobody Human papillomaviruses HPV oncoproteins HPV-associated cancer HPV cancer therapy asthma refractory asthma biomarker n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry Recent Advances in Antibody Therapeutics |
| title | Recent Advances in Antibody Therapeutics |
| title_full | Recent Advances in Antibody Therapeutics |
| title_fullStr | Recent Advances in Antibody Therapeutics |
| title_full_unstemmed | Recent Advances in Antibody Therapeutics |
| title_short | Recent Advances in Antibody Therapeutics |
| title_sort | recent advances in antibody therapeutics |
| topic | interleukin 33 ST2 receptor scFv C2_2E12 bladder cancer antibodies immune checkpoint inhibitors antibody-drug conjugates sacituzumab govitecan enfortumab vedotin erdafitinib cost-effectiveness G protein-coupled receptor membrane protein antigen therapeutic antibody anti-angiogenesis delta-like ligand irinotecan paclitaxel VEGF SARS-CoV-2 spike protein receptor-binding domain phage display monoclonal antibody cytomegalovirus peptide/major histocompatibility complex class I complex T-cell-receptor-like antibody affinity maturation yeast surface display combinatorial antibody library agonist antibody cell fate bispecific antibodies bioassays mechanisms of action binding assays potency assays atherosclerosis inflammation antibody therapy blood–brain barrier antibody pharmacokinetics disposition biochemical and physicochemical properties Fc binding receptor-mediated transcytosis brain shuttle molecular Trojan horse transferrin anti-cancer antibody antibody engineering biophysical properties computational methods research cell bank antibody therapeutics recombinant antibodies intracellular antibodies single-chain antibody fragment nanobody Human papillomaviruses HPV oncoproteins HPV-associated cancer HPV cancer therapy asthma refractory asthma biomarker n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry |
| topic_facet | interleukin 33 ST2 receptor scFv C2_2E12 bladder cancer antibodies immune checkpoint inhibitors antibody-drug conjugates sacituzumab govitecan enfortumab vedotin erdafitinib cost-effectiveness G protein-coupled receptor membrane protein antigen therapeutic antibody anti-angiogenesis delta-like ligand irinotecan paclitaxel VEGF SARS-CoV-2 spike protein receptor-binding domain phage display monoclonal antibody cytomegalovirus peptide/major histocompatibility complex class I complex T-cell-receptor-like antibody affinity maturation yeast surface display combinatorial antibody library agonist antibody cell fate bispecific antibodies bioassays mechanisms of action binding assays potency assays atherosclerosis inflammation antibody therapy blood–brain barrier antibody pharmacokinetics disposition biochemical and physicochemical properties Fc binding receptor-mediated transcytosis brain shuttle molecular Trojan horse transferrin anti-cancer antibody antibody engineering biophysical properties computational methods research cell bank antibody therapeutics recombinant antibodies intracellular antibodies single-chain antibody fragment nanobody Human papillomaviruses HPV oncoproteins HPV-associated cancer HPV cancer therapy asthma refractory asthma biomarker n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PN Chemistry |
| url | ONIX_20220706_9783036543536_3 |